Share on LinkedInShare on LinkedIn

ARTICLE · 17 NOVEMBER 2020

A Success Story (So Far!) In Drafting A Patent Application

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Plaintiffs Genentech and InterMune brought a Hatch-Waxman patent infringement action against various generic pharmaceutical companies.

United StatesIntellectual Property

Holding: In Genentech, Inc. v. Aurobindo Pharma Limited, No. 19-cv-78-RGA, 2020 WL 6144696, (D. Del. Oct. 20, 2020), United States District Court for the District of Delaware (Judge Richard G. Andrews) held that the term "Grade 2 abnormality in one or more biomarkers of liver function," as recited in three asserted patents, U.S. Pat. Nos. 7,566,729; 7,635,707; and 8,592,462, is not indefinite, and adopted Plaintiffs' proposed claim construction.

Background: Plaintiffs Genentech and InterMune brought a Hatch-Waxman patent infringement action against various generic pharmaceutical companies. Id. at *2. The case turned on the construction of the claim term "Grade 2 abnormality in one or more biomarkers of liver function," as recited in various asserted claims of the three asserted patents. Id.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from